Overview Financials News + Filings Key Docs Charts Ownership Insiders |
Sarepta Therapeutics, Inc. (SRPT)
|
Add to portfolio |
|
|
Price: |
$90.42
| | Metrics |
OS: |
88.0
|
M
| |
-132
|
% ROE
|
Market cap: |
$7.96
|
B
| |
-33
|
% ROIC
|
Net cash:
|
$1.99
|
B
| |
$22.61
|
per share
|
EV:
|
$5.97
|
B
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
($485)
|
M
| |
|
|
EBIT
|
($526)
|
M
| |
|
|
EPS |
($5.95)
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
Revenues | 843.8 | 612.4 | 455.9 | 380.8 | 301.0 | 154.6 | 5.4 | 1.3 |
Revenue growth | 37.8% | 34.3% | 19.7% | 26.5% | 94.7% | 2751.6% | 332.6% | -87.2% |
Cost of goods sold | 592.1 | 288.4 | 273.9 | 352.2 | 34.2 | 7.4 | 0.1 | 0.0 |
Gross profit | 251.6 | 324.0 | 182.0 | 28.6 | 266.8 | 147.2 | 5.3 | 1.3 |
Gross margin | 29.8% | 52.9% | 39.9% | 7.5% | 88.6% | 95.2% | 98.1% | 100.0% |
Selling, general and administrative | 877.1 | 873.2 | 830.4 | 734.1 | 207.8 | 122.7 | 83.7 | 75.0 |
Research and development | 877.1 | 771.2 | 722.3 | 560.9 | 401.8 | 166.7 | 188.3 | 146.4 |
EBITA | -535.5 | -357.0 | -455.4 | -531.5 | -342.8 | -45.6 | -266.7 | -220.2 |
EBITA margin | -63.5% | -58.3% | -99.9% | -139.6% | -113.9% | -29.5% | -4919.8% | -17572.5% |
Amortization of intangibles | 0.7 | 0.7 | 0.7 | 0.8 | 0.9 | 1.1 | 0.0 | |
EBIT | -536.2 | -357.7 | -456.1 | -532.3 | -343.6 | -46.6 | -266.7 | -220.2 |
EBIT margin | -63.5% | -58.4% | -100.1% | -139.8% | -114.1% | -30.2% | -4920.3% | -17572.5% |
Pre-tax income | -690.0 | -418.9 | -553.1 | -713.9 | -362.6 | -48.6 | -267.3 | -220.0 |
Income taxes | 13.5 | -0.2 | 1.1 | 1.2 | -0.7 | 2.1 | 0.0 | 0.0 |
Tax rate | | 0.0% | | | 0.2% | | 0.0% | 0.0% |
Net income | -703.5 | -418.8 | -554.1 | -715.1 | -361.9 | -50.7 | -267.3 | -220.0 |
Net margin | -83.4% | -68.4% | -121.6% | -187.8% | -120.2% | -32.8% | -4930.2% | -17560.3% |
|
Diluted EPS | ($8.03) | ($5.15) | ($7.11) | ($9.71) | ($5.46) | ($0.86) | ($5.49) | ($5.20) |
Shares outstanding (diluted) | 87.6 | 81.3 | 78.0 | 73.6 | 66.3 | 58.8 | 48.7 | 42.3 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|